Jonathan Zalevsky, an insider at Nektar Therapeutics (NASDAQ:NKTR), sold 180 shares of the company’s stock on February 18th for a total of $13,140, bringing his direct ownership to 21,174 shares. This follows previous sales in January and November. The stock is currently trading near $73.73, and while analysts have a “Moderate Buy” consensus rating with a target of approximately $119.86, Zacks has trimmed some near-term estimates.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Jonathan Zalevsky Sells 180 Shares of Nektar Therapeutics (NASDAQ:NKTR) Stock
Jonathan Zalevsky, an insider at Nektar Therapeutics (NASDAQ:NKTR), sold 180 shares of the company’s stock on February 18th for a total of $13,140, bringing his direct ownership to 21,174 shares. This follows previous sales in January and November. The stock is currently trading near $73.73, and while analysts have a “Moderate Buy” consensus rating with a target of approximately $119.86, Zacks has trimmed some near-term estimates.